Umlobi: Janice Evans
Usuku Lokudalwa: 27 Ujulayi 2021
Ukuvuselela Usuku: 16 Unovemba 2024
Anonim
Try Lactobacillus Bifidobacterium for Depression – Natural Remedies for Depression – Dr.Berg
Ividiyo: Try Lactobacillus Bifidobacterium for Depression – Natural Remedies for Depression – Dr.Berg

-Delile

I-Bifidobacteria yiqembu lama-bacteria avame ukuhlala emathunjini. Zingakhuliswa ngaphandle komzimba bese zithathwa ngomlomo njengomuthi.

I-bifidobacteria ijwayele ukusetshenziselwa uhudo, ukuqunjelwa, ukuphazamiseka kwamathumbu okubizwa nge-irritable bowel syndrome, ukuvimbela umkhuhlane noma umkhuhlane, kanye nezinye izimo eziningi, kepha abukho ubufakazi obuhle besayensi obusekela okuningi kwalokhu kusetshenziswa.

Isifo seCoronavirus 2019 (COVID-19): Abukho ubufakazi obuhle bokusekela ukusebenzisa i-bifidobacteria ye-COVID-19. Landela izindlela zokuphila ezinempilo nezindlela zokuvikela ezifakazelwe esikhundleni salokho.

Imibhalo Yemvelo Yemininingwane Ephelele ukukala ukusebenza ngokuncike ebufakazini besayensi ngokwesilinganiso esilandelayo: Okusebenzayo, Okungenzeka Kusebenze, Okungenzeka Kusebenze, Okungenzeka Kungasebenzi, Cishe Okungaphumeleli, Ukungasebenzi, Nobufakazi Obunganele Bokulinganisa.

Izilinganiso zokusebenza ze BIFIDOBACTERIA zimi kanje:

Kungenzeka kusebenze ...

  • Ukuqunjelwa. Ucwaningo oluningi lukhombisa ukuthi ukuthatha i-bifidobacteria kungakhuphula ukuhamba kwamathumbu cishe ngezihlalo eziyi-1.5 ngesonto kubantu abanokuqunjelwa. Kepha akuzona zonke izingqinamba ze-bifidobacteria ezibonakala zisebenza.
  • Ukutheleleka kokugaya ukudla okungaholela ezilondeni (Helicobacter pylori noma H. ​​pylori). Ukuthatha i-bifidobacteria kanye ne-lactobacillus kanye ne-standard H. pylori therapy kungasiza ukuqeda ukutheleleka kwe-H. pylori cishe kabili kanye nokuthatha ukwelashwa okujwayelekile kwe-H. pylori kukodwa. Kunganciphisa nemiphumela emibi efana nohudo kanye nokunambitheka okungalungile okuvela ku-H. pylori therapy.
  • Ukuphazamiseka kwesikhathi eside kwamathumbu amakhulu okubangela ubuhlungu besisu (i-irritable bowel syndrome noma i-IBS). Ucwaningo oluningi lukhombisa ukuthi ukuthatha i-bifidobacteria amasonto ama-4-8 kunganciphisa izimpawu ze-IBS ezinjengobuhlungu besisu, ukuqunjelwa, nobunzima bokuhamba kwamathumbu. Kunganciphisa nezimpawu ezinjengokukhathazeka nokudangala kubantu abane-IBS. Kepha akuzona zonke izingqinamba ze-bifidobacteria ezibonakala zisebenza.
  • Inkinga ngemuva kokuhlinzwa kwe-ulcerative colitis (pouchitis). Ukuthatha inhlanganisela ye-bifidobacteria ne-lactobacillus, ene-streptococcus noma engenayo, ngomlomo kubonakala kusiza ukuvimbela i-pouchitis ngemuva kokuhlinzwa kwe-ulcerative colitis.
  • Ukutheleleka kwemigwaqo yomoya. Ucwaningo oluningi lukhombisa ukuthi ukusebenzisa ama-probiotic aqukethe i-bifidobacteria kusiza ukuvikela ukutheleleka komoya njengamakhaza avamile kubantu abaphile kahle, kufaka phakathi izingane ezinesikole kanye nabafundi basekolishi. Kepha ukuthatha i-bifidobacteria kubonakala kunganciphisi ubungozi bokutheleleka komoya ezinganeni nasezibhedlela ezisencane noma kubantu abadala asebekhulile.
  • Uhudo olubangelwa yi-rotavirus. Ukunikeza izinsana ezine-bifidobacteria ezinesifo sohudo se-rotaviral kunganciphisa isikhathi sohudo cishe ngosuku olulodwa.
  • Uhudo lwabahambi. Ukuthatha i-bifidobacteria kusiza ukuvikela uhudo lwabahambi lapho lusetshenziswa namanye ama-probiotic afana ne-lactobacillus noma i-streptococcus.
  • Uhlobo lwesifo samathumbu esivuthayo (ulcerative colitis). Ucwaningo lukhombisa ukuthi ukuthatha ama-probiotic aqukethe i-bifidobacteria kanye ne-lactobacillus ne-streptococcus kungasiza ukukhuphula izinga lokuxolelwa cishe cishe izikhathi ezimbili kubantu abane-ulcerative colitis. Kodwa-ke, ucwaningo oluningi lukhombisa ukuthi i-bifidobacteria ayilusizo ekuvimbeleni ukubuyela emuva.

Kungenzeka kungasebenzi ku ...

  • Nciphisa amakhono wokukhumbula nokucabanga okwenzeka ngokujwayelekile ngobudala. I-bifidobacteria ayibonakali ithuthukisa amakhono okucabanga nokukhumbula kubantu abadala asebekhulile ngokwehla kwamakhono okucabanga.
  • Ukutheleleka komgudu wamathumbu ngamagciwane abizwa ngeClostridium difficile. Ucwaningo oluningi lukhombisa ukuthi ukuthatha i-bifidobacteria kanye namanye ama-probiotic akuvimbeli isifo sohudo esibangelwa ukutheleleka kweClostridium difficile.
  • Ukukhula kwengane. Ukunikeza ifomula eliqukethe i-bifidobacteria kanye ne-lactobacillus akukuthuthukisi ukukhula kwezinsana.
  • Ukukhuluphala ngokweqile. Ucwaningo oluningi lukhombisa ukuthi ukuthatha i-bifidobacteria izinyanga ezifika kwezingu-6 akukuthuthukisi ukuncipha kwesisindo kubantu abakhuluphele ngokweqile noma abakhuluphele ngokweqile.
  • Ukutheleleka ngegazi (sepsis). Ukungeza i-bifidobacteria kwifomula yezinsana akuvimbeli i-sepsis ezinganeni ezizalwe ngaphambi kwesikhathi.

Ubufakazi obanele bokukala ukusebenza kwe ...

  • Uhudo kubantu abathatha ama-antibiotic (isifo sohudo esihlobene ne-antibiotic). Ucwaningo lukhombisa ukuthi ukuthatha i-bifidobacteria kanye nama-antibiotics kunganciphisa ithuba lohudo cishe ngama-45%. Kepha eminye imiphumela ephikisanayo ikhona. Kungenzeka ukuthi i-bifidobacteria ingavimbela isifo sohudo esibangelwa amanye ama-antibiotic kodwa hhayi amanye. Futhi, i-bifidobacteria ingasebenza kangcono uma isetshenziswa enhlanganisweni ethile ne-lactobacillus ne-streptococcus. Kepha akuyona yonke inhlanganisela ebonakala isebenza.
  • Ukusebenza kwezemidlalo. Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-bifidobacteria kusiza abasubathi abaqeqeshiwe ukugijimela kude ngesikhathi esifanayo.
  • I-eczema (i-atopic dermatitis). Olunye ucwaningo lukhombisa ukuthi ukunikeza i-bifidobacterium ezinganeni kungasiza UKULAPHA i-eczema, kepha imiphumela ephikisanayo ikhona. Olunye ucwaningo lukhombisa ukuthi ukunikeza i-bifidobacteria kanye ne-lactobacillus kwabesifazane abakhulelwe ezinyangeni ezi-2 zokugcina zokukhulelwa, bese unikeza usana izinyanga ezimbili zokuqala ngemuva kokuzalwa, kungasiza UKUVIMBELA i-eczema. Kepha kunemiphumela ephikisanayo. Ukunikeza izinsana ezisengozini kuphela phakathi nezinyanga eziyisithupha zokuqala zokuphila akuvimbeli i-eczema.
  • Isifo seCeliac. Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-bifidobacteria njengengxenye yokudla okungenayo i-gluten akwenzi ngcono izimpawu zesisu namathumbu uma kuqhathaniswa nokudla kuphela ezinganeni ezinezifo ze-celiac ezisanda kutholakala.
  • Nciphisa amakhono okukhumbula nawokucabanga kubantu asebekhulile okungaphezu kokujwayelekile ngeminyaka yabo. Olunye ucwaningo lukhombisa ukuthi ukuthatha i-bifidobacteria kuthuthukisa inkumbulo kubantu abanokwehla kwamakhono okucabanga, kodwa akubonakali kusiza ngolimi noma amandla okunaka.
  • Uqwembe lwamazinyo. Ucwaningo lwakuqala lukhombisa ukuthi ukudla i-yogurt yezithelo nge-bifidobacteria amasonto ama-2 akulinciphisi uqweqwe lwamazinyo ezinganeni.
  • Uhudo. Ucwaningo lwakuqala lwathola ukuthi ukwengeza i-bifidobacteria ku-Saccharomyces boulardii kuxhunyaniswa nokuqhubeka nokunciphisa isifo sohudo ezinganeni ezinesifo sohudo ngokuzumayo.
  • Ukungezwani komzimba nempova yemisedari yaseJapan. Olunye ucwaningo lukhombisa ukuthi ukuthatha i-bifidobacteria ngesikhathi sempova kunciphisa izimpawu zekhala nezamehlo zokungezwani komzimba ne-Japanese cedar pollen. Kepha imiphumela ephikisanayo ikhona. I-bifidobacteria ibonakala inganciphisi ukuthimula noma izimpawu zomphimbo ezihambisana nokungezwani komzimba neJapan.
  • Isifo esibi samathumbu ezinganeni ezingakazalwa ngaphambi kwesikhathi (necrotizing enterocolitis noma i-NEC). Ucwaningo lukhombisa ukuthi ukunikela nge-bifidobacteria yodwa ezinganeni ezizalwe ngaphambi kwesikhathi akuvimbeli lesi simo. Kodwa ukunikeza i-bifidobacteria nge-lactobacillus kungaba nenzuzo encane.
  • Ukugula okubucayi okubangelwa ukuvezwa yimisebe. Ucwaningo lwakuqala lukhombisa ukuthi i-bifidobacteria emelana nemithi elwa namagciwane ingasiza ekuthuthukiseni ukusinda kwesikhashana ekwelapheni ukugula ngemisebe. Ngokuhlanganiswa nama-antibiotic, i-bifidobacteria ibonakala isiza ukuvimbela amagciwane ayingozi ukuthi angakhuli futhi abangele ukutheleleka okungathi sína.
  • Isifo samathambo (RA).
  • Ukutheleleka kwezinso, isinye, noma i-urethra (izifo ezithinta umchamo noma ama-UTIs).
  • Ukuguga.
  • Ubuhlungu besifuba, mhlawumbe ngenxa yokutheleleka (i-mastitis).
  • Umdlavuza.
  • Ukuphazamiseka kwe-bipolar.
  • Ukutheleleka kubantu abaphathwa ngemithi yomdlavuza.
  • Ukukhula kwengane.
  • Ukukhula nentuthuko ezinganeni ezingaphambi kwesikhathi.
  • Ukugeleza okuncishisiwe noma okuvinjiwe kwesibindi esibindini (cholestasis).
  • Isifo sikashukela.
  • Ukungabekezelelani kwe-Lactose.
  • Izinkinga zesibindi.
  • Isifo seLyme.
  • Izimpumputhe.
  • Ubuhlungu bemisipha obubangelwa ukuzivocavoca umzimba.
  • Izinga eliphakeme le-cholesterol noma amanye amafutha (lipids) egazini (hyperlipidemia).
  • Ukuvuvukala (ukuvuvukala) nokwakha amafutha esibindini kubantu abaphuza utshwala obuncane noma abangaphuzi (nonalcoholic steatohepatitis or NASH).
  • Ukuvuvukala (ukuvuvukala) nezilonda ngaphakathi komlomo (i-oral mucositis).
  • Uhudo olubangelwa ukwelashwa ngemisebe.
  • Ukushintsha amagciwane azuzisayo asuswe ngohudo.
  • Izinkinga zesisu.
  • I-Thrush.
  • Ezinye izimo.
Kudingeka ubufakazi obuningi ukukala i-bifidobacteria yalokhu kusetshenziswa.

Amagciwane amaningi nezinye izinto eziphilayo zihlala emizimbeni yethu ngokujwayelekile. Amagciwane "anobungane" afana ne-bifidobacteria angasisiza ukuthi sihlukanise ukudla, simunce izakhi zomzimba, silwe nezinto eziphilayo "ezingenabungane" ezingadala izifo ezifana nohudo.

Lapho ithathwa ngomlomo: Bifidobacteria kukhona CISHE UVIKILE kubantu abadala abanempilo lapho bethathwa ngomlomo ngokufanele. Kwabanye abantu, ukwelashwa nge-bifidobacteria kungaphazamisa isisu namathumbu, kubangele isifo sohudo, ukuqumba kanye negesi.

Ukuqapha okukhethekile nezixwayiso:

Ukukhulelwa nokuncelisa ibeleUhlobo oluthile lwe-bifidobacteria, i-Bifidobacterium bifidum, yi OKUNGENZEKA UKUPHEPHA lapho ithathwa ngomlomo ngokufanele amasonto ayisithupha ngenkathi ukhulelwe. Akukho lwazi olwanele ngokwanele mayelana nokuphepha kokuthatha ezinye izinhlobo ze-bifidobacteria uma ukhulelwe noma uncelisa ibele. Hlala ohlangothini oluphephile futhi ugweme ukusetshenziswa.

Izingane: Bifidobacteria kukhona CISHE UVIKILE yezingane ezinesizotha lapho zithathwa ngomlomo ngokufanele. Yize kube nezimo zokutheleleka ngegazi nge-bifidobacteria ezinganeni ezigula kakhulu, lawa macala angavamile.

Amasosha omzimba abuthakathaka: Kukhona ukukhathazeka ngokuthi "ama-probiotic" angakhula kahle kakhulu kubantu abanamasosha omzimba abuthakathaka futhi abangele ukutheleleka. Yize lokhu kungenzekanga ngqo nge-bifidobacteria, kube nezimo ezingavamile ezibandakanya ezinye izinhlobo zama-probiotic njengeLactobacillus. Uma unamasosha omzimba abuthakathaka (isb. Une-HIV / AIDS noma uthola ukwelashwa komdlavuza), hlola umhlinzeki wakho wezokunakekelwa kwempilo ngaphambi kokusebenzisa i-bifidobacteria.

Ukuvaleka emathunjini: Kubikwe izehlakalo ezimbili zokutheleleka ngegazi ezinganeni ezinikezwe ama-bifidobacteria probiotic. Kuzo zombili lezi zimo, izinsana bezihlinzwa isisu. Kucatshangwa ukuthi ukutheleleka kwegazi kubangelwe ukuvinjelwa kwamathumbu okubangelwe ukuhlinzwa kwesisu, obekuvumela i-bifidobacteria ukuthi iwele iye egazini. Kwesinye isimo, ukuthatha i-bifidobacteria ngemuva kokulungiswa kokuvinjelwa kwamathumbu akubanga elinye igciwane legazi. Ngakho-ke ubungozi bokutheleleka ngegazi akuyona inkinga yezinsana eziningi ezithatha i-bifidobacteria. Kepha i-bifidobacteria kufanele isetshenziswe ngokuqapha noma igwenywe ezinganeni ezinokuvinjelwa esiswini noma kwamathumbu.

Maphakathi
Qaphela ngale nhlanganisela.
Imithi elwa namagciwane
Ama-antibiotic asetshenziselwa ukunciphisa amabhaktheriya ayingozi emzimbeni. Ama-antibiotic nawo anganciphisa amabhaktheriya anobungane emzimbeni. I-bifidobacteria uhlobo lwama-bacteria anobungane. Ukuthatha ama-antibiotics kanye ne-bifidobacteria kunganciphisa ukusebenza kwe-bifidobacteria. Ukugwema lokhu kuhlangana, thatha imikhiqizo ye-bifidobacteria okungenani amahora amabili ngaphambi noma ngemuva kwama-antibiotic.
Akukho ukuxhumana okwaziwayo ngamakhambi nezengezo.
Akukho ukuxhumana okwaziwayo nokudla.
Imithamo elandelayo ifundwe ocwaningweni lwesayensi:

ABADALA

NGOMLOMO:
  • Okokuqunjelwa: Amayunithi ayizigidi eziyikhulu kuya kweziyizigidi ezingama-20 akha amakoloni e-bifidobacteria asetshenziswe nsuku zonke. Ezimweni eziningi, i-bifidobacteria ithathwa nsuku zonke amaviki angu-1-4. Kwezinye izimo amayunithi angama-5-60 billion akha amakoloni we-bifidobacteria kanye ne-lactobacillus athathwe nsuku zonke isonto elilodwa kuya enyangeni e-1.
  • Ngokuphazamiseka kwesikhathi eside kwamathumbu amakhulu okubangela ubuhlungu besisu (i-irritable bowel syndrome noma i-IBS): Ekwenzeni ngcono izimpawu zesisu namathumbu, amayunithi ayizigidi eziyi-100 kuya ku-1 billion akha amakoloni we-bifidobacteria asetshenziswe nsuku zonke amasonto ama-4-8. Futhi, amayunithi ayizigidi eziyizinkulungwane ezinhlanu akha amakoloni e-bifidobacteria kanye ne-lactobacillus kanye ne-streptococcus asetshenziswe kabili nsuku zonke amasonto ama-4. Ukwenza ngcono ukucindezeleka nokukhathazeka kubantu abane-IBS, amayunithi ayizigidi eziyizinkulungwane eziyishumi akha amakoloni e-bifidobacteria asetshenziswe kanye ngosuku amasonto ayisithupha.
  • Ngokutheleleka kwemigwaqo yomoya: Amayunithi we-bifidobacteria ayizigidi eziyizinkulungwane ezi-3 asetshenziswe nsuku zonke amaviki ayisithupha.
  • Ngenkinga ngemuva kokuhlinzwa kwe-ulcerative colitis (pouchitis): umthamo ongafika ezigidini ezi-3 trillion zokwakha amakoloni we-bifodobacteria kanye ne-lactobacillus kanye ne-streptococcus unikezwe kanye ngosuku kuze kube izinyanga eziyi-12.
  • Ngokutheleleka kokugaya ukudla okungaholela ezilondeni (Helicobacter pylori noma H. ​​pylori): Kusetshenziswe amayunithi ayizigidi eziyizinkulungwane ezinhlanu akha amakoloni e-bifidobacteria kanye ne-lactobacillus nsuku zonke isonto elilodwa ngesikhathi sokwelashwa kuka-H. pylori kanye neviki elilodwa ngemuva kwalokho kusetshenzisiwe.
  • Uhlobo lwesifo samathumbu esivuthayo (ulcerative colitis): Ekhulisweni elikhulayo, amagremu ama-3 alingana namayunithi we-lactobacillus kanye ne-bifidobacteria kanye ne-streptococcus asetshenzisiwe kanye noma kabili ngosuku.
IZINGANE

NGOMLOMO:
  • Okokuqunjelwa: Kusetshenziswe amayunithi we-bifidobacteria ayizigidi eziyizinkulungwane eziyi-1-100 nsuku zonke amasonto ama-4 asetshenziswe ezinganeni ezineminyaka engu-3-16.
  • Ukuphazamiseka kwesikhathi eside kwamathumbu amakhulu okubangela ubuhlungu besisu (i-irritable bowel syndrome noma i-IBS)Kusetshenziswe amayunithi ayizigidi eziyizinkulungwane eziyishumi akha amakoloni e-bifidobacteria nsuku zonke amasonto ama-4.
  • Ngokutheleleka kwemigwaqo yomoya: Amayunithi we-2-10 billion wokwakha amakoloni enhlanganisela ye-bifidobacteria kanye ne-lactobacillus asetshenziswe kabili nsuku zonke ezinganeni ezineminyaka engama-3-13.
  • Ngesifo sohudo esibangelwa i-rotavirus: I-Bifidobacteria, kanye noma ne-streptococcus, isetshenziswe ezinganeni ezineminyaka engama-3 ubudala. Futhi, i-bifidobacteria kanye ne-lactobacillus isetshenziswe kabili nsuku zonke izinsuku ezintathu.
  • Uhlobo lwesifo samathumbu esivuthayo (ulcerative colitis): Kuze kube ngamayunithi we-1.8 trillion akha amakoloni we-bifidobacteria kanye ne-lactobacillus kanye ne-streptococcus isetshenziswe nsuku zonke kuze kube unyaka owodwa ezinganeni ezineminyaka engu-1-16 ubudala.
B. Bifidum, B. Breve, B. Infantis, B. lactis, B. Longum, Bifido, Bifido Bacterium Longum, Bifidobacterias, Bifidobactérie, Bifidobactéries, Bifidobacterium, Bifidobacterium osemusha; Bifidobacterium animalis, Bifidobacterium bifidum; IBifidobacterium breve; I-Bifidobacterium infantis; I-Bifidobacterium lactis; Bifidobacterium longum, Bifidum, Bifidus, Bifidus Brevis, Bifidus Infantis, Bifidus Longum, Bifidobacteria Bifidus, Lactobacillus Bifidus, L. Bifidus, Probiotic, Probiotique.

Ukuze ufunde kabanzi ngokuthi le ndatshana ibhalwe kanjani, sicela ubheke ifayela le- Imibhalo Yemvelo Yemininingwane Ephelele indlela.


  1. U-Athalye-Jape G, Minaee N, uNathan E, et al. Imiphumela yokuqala okuncane kuqhathaniswa nezinsana zokubeletha ngemuva kwe-Bifidobacterium breve M-16 V supplementation. J Matern Fetal Neonatal Med. 2020; 33: 2209-2215. Buka okungaqondakali.
  2. UWu G, Chen X, uCui N, et al. Umphumela wokuvimbela we-Bifidobacterium supplementation ku-neonatal cholestasis kuma-preterm neonates anesisindo esiphansi kakhulu sokuzalwa. IGastroenterol Res Pract. 2020; 2020: 4625315. Buka okungaqondakali.
  3. UXiao J, uKatsumata N, uBernier F, et al. I-Probiotic bifidobacterium breve ekuthuthukiseni imisebenzi yokuqonda yabantu abadala asebekhubazekile okusolakala ukuthi kunengqondo: Isivivinyo esilawulwa ngokungahleliwe, esingaboni kabili, esilawulwa yi-placebo. UJ Alzheimers Dis. 2020; 77: 139-147. Buka okungaqondakali.
  4. ILin CL, Hsu YJ, Ho HH, et al. I-Bifidobacterium longum subsp. ukwesekwa kwe-longum OLP-01 ngesikhathi sokuqeqeshwa kokukhuthazela kuthuthukisa ukusebenza kokuzivocavoca kubagijimi abaphakathi nasebangeni elide: Isivivinyo esilawulwa izimpumputhe. Izakhamzimba. 2020; 12: 1972. Buka okungaqondakali.
  5. U-Lewis ED, u-Antony JM, uCrowley DC, et al. Ukusebenza kweLactobacillus paracasei HA-196 neBifidobacterium longum R0175 ekwehliseni izimpawu zesifo samathumbu (IBS): Ucwaningo olulawulwa ngokungahleliwe. Izakhamzimba. 2020; 12: 1159. Buka okungaqondakali.
  6. UMichael DR, Jack AA, Masetti G, et al. Ucwaningo olulawulwa ngokungahleliwe lubonisa ukulekelelwa kwabantu abadala abakhuluphele nabakhuluphele ngokweqile abane-lactobacilli ne-bifidobacteria yehlisa ukuqina komzimba futhi ithuthukise inhlalakahle. ISci Rep. 2020; 10: 4183. Buka okungaqondakali.
  7. UCzajeczny D, Kabzi & nacute; ska K, Wójciak RW. Ingabe i-probiotic supplementation iyasiza ekunciphiseni isisindo? Ucwaningo olulawulwa ngokungahleliwe, oluyimpumputhe, olulawulwa nge-placebo nge-Bifidobacterium lactis BS01 kanye ne-Lactobacillus acidophilus LA02 supplementation. Yidla Ukungezwani Kwesisindo. 2020. Buka okungaqondakali.
  8. UJiao X, Fu MD, Wang YY, Xue J, Zhang Y. Bifidobacterium noLactobacillus wokuvimbela i-necrotizing enterocolitis ezinganeni ezinesisindo esiphansi kakhulu sokuzalwa: ukubuyekezwa okuhlelekile nokuhlaziywa kwemeta. Umhlaba J Pediatr. 2020; 16: 135-142. Buka okungaqondakali.
  9. USadeghi-Bojd S, Naghshizadian R, Mazaheri M, Ghane Sharbaf F, Assadi F. Ukusebenza kwe-probiotic prophylaxis ngemuva kokutheleleka kokuqala kokuthamba komchamo ezinganeni ezinamapheshana ajwayelekile e-urinary. J Pediatric Infect Dis Soc. 2020; 9: 305-310. Buka okungaqondakali.
  10. IButler CC, uLau M, uGillespie D, et al. Umphumela wokusetshenziswa kwama-probiotic ekuphathweni kwama-antibiotic phakathi kwabahlali basemakhaya okunakekelwa: Isivivinyo somtholampilo esingahleliwe. JAMA. 2020; 324: 47-56. Buka okungaqondakali.
  11. I-Zhu XL, i-Tang XG, i-Qu F, i-Zheng Y, i-Zhang WH, i-Diao YQ. I-Bifidobacterium ingazuza ekuvinjelweni kwe-necrotizing enterocolitis ezinganeni ezizalwe ngaphambi kwesikhathi: Ukubuyekezwa okuhlelekile nokuhlaziywa kwemeta. Int J Ukuhlinzwa. 2019; 61: 17-25. Buka okungaqondakali.
  12. UWang G, Feng D. Umphumela wokwelashwa weSaccharomyces boulardii uhlanganiswe neBifidobacterium kanye nokusebenza kwamaseli omzimba ezinganeni ezinesifo sohudo esibi. I-Exp Ther Med. 2019; 18: 2653-2659. Buka okungaqondakali.
  13. USharif A, uKashani HH, uNasri E, uSoleimani Z, uSharif MR. Iqhaza Lama-Probiotic ekwelapheni i-Dysentery: Isivivinyo Sasemtholampilo Esenziwe Ngokungahleliwe Esiphindiwe. Amaphrotheni ama-Probiotic Antimicrob. 2017; 9: 380-385. Buka okungaqondakali.
  14. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Ngabe ama-probiotic aphephile? I-Bifidobacterium bacteremia enganeni enokwehluleka okukhulu kwenhliziyo. Infez Med. 2019; 27: 175-178. Buka okungaqondakali.
  15. UManzhalii E, Virchenko O, Falalyeyeva T, Beregova T, Stremmel W. Ukwelashwa okusebenzayo kokulungiselela ama-probiotic we-steatohepatitis okungeyona eyotshwala: Isivivinyo somshayeli. UJ Dig Dis. U-2017; 18: 698-703. Buka okungaqondakali.
  16. UKobayashi Y, Kuhara T, Oki M, Xiao JZ. Imiphumela ye-Bifidobacterium breve A1 ekusebenzeni kwengqondo yabantu abadala asebekhulile abanezikhalazo zememori: isilingo esilawulwa ngokungahleliwe, esingaboni kabili, esilawulwa yi-placebo. Zuza Amagciwane. 2019; 10: 511-520. Buka okungaqondakali.
  17. UJiang C, uWang H, uXia C, et al. Isivivinyo esilawulwa ngokungahleliwe, esiyimpumputhe, esilawulwa nge-placebo sama-probiotic ukunciphisa ubunzima be-mucositis yomlomo ebangelwa yi-chemoradiotherapy yeziguli ezine-nasopharyngeal carcinoma. Umdlavuza. 2019; 125: 1081-1090. Buka okungaqondakali.
  18. U-Inoue T, uKobayashi Y, Mori N, et al. Umphumela wokuhlanganiswa kokuhlanganiswa kwe-bifidobacteria kanye nokuqeqeshwa kokumelana nokusebenza kwengqondo, ukwakheka komzimba nemikhuba yamathumbu ezifundo zabantu abadala ezinempilo. Zuza Amagciwane. 2018; 9: 843-853. Buka okungaqondakali.
  19. UDimidi E, Zdanaviciene A, Christodoulides S, et al. Isivivinyo somtholampilo esingahleliwe: I-Bifidobacterium lactis NCC2818 probiotic vs placebo, nomthelela esikhathini sokuhamba kwamathumbu, izimpawu, kanye ne-gut microbiology ekuqunjelweni okungapheli. I-Aliment Pharmacol Ther. 2019; 49: 251-264. Buka okungaqondakali.
  20. I-Caglar E. Umphumela we-Bifidobacterium bifidum equkethe iyogathi kuma-bacterial plaque wamazinyo ezinganeni. J Clin Pediatr Dent. 2014; 38: 329-32. Buka okungaqondakali.
  21. UZhang J, Ma S, Wu S, Guo C, Long S, Tan H. Imiphumela ye-Probiotic Supplement kwabesifazane abakhulelwe abane-Gestational Diabetes Mellitus: Ukubuyekezwa Okuhlelekile kanye ne-Meta-Analysis Yezilingo Ezilawulwa Ngokungahleliwe. J Isifo Sikashukela Res. 2019; 2019: 5364730. Buka okungaqondakali.
  22. USlykerman RF, uKang J, uVan Zyl N, et al. Umphumela wesengezo sokuqala se-probiotic ekuqondeni kobuntwana, ekuziphatheni nasemoyeni isilingo esilawulwa ngokungahleliwe, esilawulwa yi-placebo. I-Acta Paediatr. 2018; 107: 2172-2178. Buka okungaqondakali.
  23. USchmidt RM, uPilmann Laursen R, uBruun S, et al. Ama-Probiotic ebuntwaneni sekwephuze anciphisa izehlakalo ze-eczema: Isivivinyo esilawulwa ngokungahleliwe. I-Pediatr yokungezwani komzimba ne-Immunol. 2019; 30: 335-340. Buka okungaqondakali.
  24. I-Linn YH, Thu KK, Yinqoba i-NHH. Umphumela wama-Probiotic Wokuvimbela Imisebe Ebuhlungu Ebangelwa Uhudo Phakathi Kweziguli Ezinomdlavuza Wesibeletho: Isifundo Esilawulwa Ngendlela Engahleliwe Esilawulwa Kababili. Amaphrotheni ama-Probiotic Antimicrob. 2019; 11: 638-647. Buka okungaqondakali.
  25. UCallaway LK, uMcIntyre HD, uBarrett HL, et al. Ama-Probiotic Wokuvimbela Isifo Sikashukela Sokukhulelwa Kwabesifazane Abakhuluphele Futhi Abakhuluphele: Ukutholwa Okuvela Esivivinyweni Esilawulwa Ngokwe-SPRING Double-Blind Randomized Trial. Ukunakekelwa yisifo sikashukela. 2019; 42: 364-371. Buka okungaqondakali.
  26. UStaudacher HM, uLomer MCE, Farquharson FM, et al. Ukudla Okuphansi kuma-FODMAP Kunciphisa Izimpawu Ezigulini Ezine-Irritable Bowel Syndrome kanye ne-Probiotic Ebuyisela Izinhlobo ze-Bifidobacterium: Isivivinyo Esilawulwa Ngokungahleliwe. I-Gastroenterology. 2017; 153: 936-947. Buka okungaqondakali.
  27. UMatsuoka K, Uemura Y, Kanai T, et al. Ukusebenza kweBifidobacterium breve Milmented Milk in Maintaining Remission of Ulcerative Colitis. I-Dig Dis Sci. 2018; 63: 1910-1919. Buka okungaqondakali.
  28. U-Liu J, u-Huang XE. Ukusebenza kweBifidobacterium tetragenous viable bacteria bacteria yeziguli ezinomdlavuza ezinokuqunjelwa okusebenzayo. I-Asian Pac J Cancer Yangaphambilini. 2014; 15: 10241-4. Buka okungaqondakali.
  29. ULau AS, uYanagisawa N, Hor YY, et al. I-Bifidobacterium longum BB536 inciphise izifo eziphezulu zokuphefumula kanye namaphrofayili amancane we-gut microbiota ezinganeni zaseMalaysian pre-school. Zuza Amagciwane. I-2018; 9: 61-70. Buka okungaqondakali.
  30. Ibarra A, Latreille-Barbier M, Donazzolo Y, Pelletier X, Ouwehand AC. Imiphumela yezinsuku ezingama-28 zeBifidobacterium animalis subsp. ukwengezwa kwe-lactis HN019 esikhathini sokuhamba kwekholoni kanye nezimpawu zesisu kubantu abadala abanokuqunjelwa okusebenzayo: Isivivinyo esilawulwa kabili, esingahleliwe, esilawulwa nge-placebo, nesilinganiso semithamo. Gut Microbes. 2018; 9: 236-251. Buka okungaqondakali.
  31. U-Guardamagna O, u-Amaretti A, uPuddu PE, et al. Ukwengeza kwe-Bifidobacteria: imiphumela kumaphrofayli e-plasma lipid ezinganeni ezi-dyslipidemic. Ukudla okunomsoco. 2014; 30 (7-8): 831-6. Buka okungaqondakali.
  32. UBadehnoosh B, uKaramali M, uZarrati M, et al. Imiphumela yokwengeza kwe-probiotic kuma-biomarkers wokuvuvukala, ukucindezelwa kwe-oxidative kanye nemiphumela yokukhulelwa kusifo sikashukela sokukhulelwa. J Matern Fetal Neonatal Med. 2018 Kwangathi; 31: 1128-1136. Buka okungaqondakali.
  33. UDickerson F, Adamos M, Katsafanas E, et al. Ama-microorganisms ama-probiotic ahlanganisayo ukuvimbela ukuvuselelwa kabusha kweziguli ezine-mania enzima: Isivivinyo esilawulwa ngokungahleliwe. Ukuphazamiseka KweBipolar. 2018 Apr 25. Buka okungaqondakali.
  34. I-Pinto GS, i-Cenci MS, i-Azevedo MS, i-Epifanio M, uJones MH. Imiphumela yeyogathi equkethe iBifidobacterium animalis subsp. i-lactis DN-173010 probiotic ku-plaque yamazinyo namathe ezigulini ze-orthodontic. Ama-Caries Res. 2014; 48: 63-8. Buka okungaqondakali.
  35. UZamani B, Golkar HR, Farshbaf S, et al. Impendulo yomtholampilo neye-metabolic ekungezweni kwe-probiotic ezigulini ezinesifo samathambo: isilingo esilawulwa ngokungahleliwe, esiyimpumputhe, nesilawulwa yi-placebo. I-Int J Rheum Dis 2016; 19: 869-79. Buka okungaqondakali.
  36. IPinto-Sanchez MI, iHolo GB, uGhajar K, et al. I-Probiotic Bifidobacterium longum NCC3001 inciphisa izikolo zokuxineka futhi iguqula ukusebenza kobuchopho: isifundo somshayeli ezigulini ezinesifo samathumbu esingacasuki. I-Gastroenterology 2017; 153: 448-459.e8. Buka okungaqondakali.
  37. UKaramali M, uDadkhah F, uSadrkhanlou M, et al. Imiphumela yokwengeza kwe-probiotic ekulawuleni kwe-glycemic kanye namaphrofayli e-lipid ku-gestational diabetes: isilingo esilawulwa ngokungahleliwe, esiyimpumputhe, esilawulwa yi-placebo. Isifo Sikashukela Metab 2016; 42: 234-41. Buka okungaqondakali.
  38. UJäger R, Purpura M, Itshe JD, et al. I-Probiotic Streptococcus thermophilus FP4 ne-Bifidobacterium breve BR03 supplementation inciphisa ukusebenza kanye nokuncipha kokuhamba okulandelayo kulandela ukuvivinya umzimba okulimaza imisipha. Izakhi 2016; 8. pii: E642. Buka okungaqondakali.
  39. UWorwell PJ, Altringer L, Morel J, et al. Ukusebenza kwe-probiotic eboshiwe ye-Bifidobacterium infantis 35624 kwabesifazane abane-bowel syndrome ecasulayo. NginguJ Gastroenterol. 2006 Julayi; 101: 1581-90. Buka okungaqondakali.
  40. ILau CS, uChamberlain RS. Ama-Probiotic ayasebenza ekuvimbeleni isifo sohudo esihambisana neClostridium difficile: ukubuyekeza okuhlelekile nokuhlaziywa kwemeta. Int J Gen Med. 2016; 9: 27-37. Buka okungaqondakali.
  41. UStenman LK, uLehtinen MJ, uMeland N, et al. I-Probiotic With or Without Fiber Controls Body Fat Mass, Ehambisana NeSerum Zonulin, Esivivinyweni Esilawulwa Ngabantu Abakhulu Kakhulu Nabakhulu ngokweqile. I-EBioMedicine 2016; 13: 190-200. Buka okungaqondakali.
  42. USato S, Uchida T, Kuwana S, et al. I-Bacteremia eyenziwe yi-Bifidobacterium breve enganeni esanda kuzalwa ene-cloacal exstrophy. I-Pediatr Int. 2016; 58: 1226-8. Buka okungaqondakali.
  43. UJayasimhan S, Yap NY, Roest Y, Rajandram R, Chin KF. Ukusebenza kokulungiswa kwamaseli ama-microbial ekwenzeni ngcono ukuqunjelwa okungapheli: isilingo esilawulwa ngokungahleliwe, esiyimpumputhe, esilawulwa yi-placebo. Umtholampilo Wezempilo 2013; 32: 928-34. Buka okungaqondakali.
  44. UHan K, uWang J, u-Seo JG, uKim H. Ukusebenza kwama-probiotiki aboshwe kabili wesifo samathumbu esibuhlungu: isilingo esilawulwa ngokungahleliwe. UJ Gastroenterol. 2017; 52: 432-443. Buka okungaqondakali.
  45. Chang HY, Chen JH, Chang JH, Lin HC, Lin CY, Peng CC. Ama-probiotic wamagciwane amaningi abonakala njengama-probiotic asebenza kakhulu ekuvikeleni i-necrotizing enterocolitis kanye nokufa: Ukuhlaziywa kwe-meta-ukuhlaziywa. Ama-PLoS One. 2017; 12: e0171579. Buka okungaqondakali.
  46. I-Bastürk A, u-Artan R, u-Yilmaz A. Ukusebenza kahle kwe-synbiotic, i-probiotic, kanye nokwelashwa kwama-prebiotic kwesifo samathumbu esibuhlungu ezinganeni: Isivivinyo esilawulwa ngokungahleliwe. I-Turk J Gastroenterol 2016; 27: 439-43. Buka okungaqondakali.
  47. IBlaabjerg S, Artzi DM, Aabenhus R. Probiotic for the Prevention of Antibiotic-Associated Diarrhea in Outpatients-A Systematic Review and Meta-Analysis. Ama-Antibiotic (iBasel). 2017; 6. Buka okungaqondakali.
  48. I-Al Faleh K, i-Anabrees J. Probiotic yokuvimbela i-necrotizing enterocolitis ezinganeni ezizalwe ngaphambi kwesikhathi. ICochrane Database Syst Rev. 2014;: CD005496. Buka okungaqondakali.
  49. UDimidi E, Christodoulides S, Fragkos KC, Scott SM, Whelan K. Umphumela wama-probiotic ekuqunjelweni okusebenzayo kubantu abadala: ukubuyekezwa okuhlelekile nokuhlaziywa kwe-meta-kwezivivinyo ezilawulwa ngokungahleliwe. Ngingu-J J Nutriti Womtholampilo. 2014; 100: 1075-84. Buka okungaqondakali.
  50. UWildt S, uNordgaard I, uHansen U, uBrockmann E, uRumessen JJ. Isilingo esilawulwa ngokungahleliwe esilawulwa yi-placebo nge-Lactobacillus acidophilus La-5 neBifidobacterium animalis subsp. i-lactis BB-12 yokugcinwa kokuxolelwa ku-ulcerative colitis. UJ Crohns Colitis 2011; 5: 115-21. Buka okungaqondakali.
  51. UShen J, Zuo ZX, Mao AP. Umphumela wama-probiotic ekunciphiseni ukuxolelwa nasekugcineni ukwelashwa ku-ulcerative colitis, isifo sikaCrohn, ne-pouchitis: ukuhlaziywa kwe-meta kokuhlolwa okungahleliwe. I-Inflamm Bowel Dis. 2014; 20: 21-35. Buka okungaqondakali.
  52. IPaki MS, Kwon B, Ku S, Ji GE4. Ukusebenza kweBifidobacterium longum BORI neLactobacillus acidophilus AD031 Probiotic Treatment ezinganeni ezine-Rotavirus Infection. Izakhamzimba. 2017; 9. pii: E887. Buka okungaqondakali.
  53. I-Søndergaard B, i-Olsson J, i-Ohlson K, i-Svensson U, i-Bytzer P, i-Ekesbo R.Imiphumela yobisi oluvutshiwe lwe-probiotic kwizimpawu kanye nezimbali zamathumbu ezigulini ezinesifo samathumbu esicasulayo: isilingo esilawulwa ngokungahleliwe, esilawulwa yi-placebo. IScand J Gastroenterol 2011; 46: 663-72. Buka okungaqondakali.
  54. USimrén M, Ohman L, Olsson J, et al. Isivivinyo somtholampilo: imiphumela yobisi oluvutshiwe oluqukethe amabhaktheriya amathathu ama-probiotic ezigulini ezine-syndrome ecasulayo yamathumbu - isifundo esilawulwa ngokungahleliwe, esingaboni kabili, esilawulwayo. I-Aliment Pharmacol Ther 2010; 31: 218-27. Buka okungaqondakali.
  55. IGoldenberg JZ, uLytvyn L, uSteurich J, uParkin P, uMahant S, uJohnston BC. Ama-Probiotic wokuvimbela isifo sohudo esihambisana nezingane. ICchrane Database Syst Rev. 2015;: CD004827. Buka okungaqondakali.
  56. O’Callaghan A, van Sinderen D. Bifidobacteria neqhaza labo njengamalungu eHuman Gut Microbiota. Ngaphambili Microbiol. 2016 Juni 15; 7: 925. Buka okungaqondakali.
  57. U-Olivares M, uCastillejo G, uVarea V, uSanz Y.Isivivinyo sokungenelela esilawulwa kabili, esingahleliwe, esilawulwa yi-placebo sokuhlola imiphumela yeBifidobacterium longum CECT 7347 ezinganeni ezinezifo ze-celiac ezisanda kutholakala. UBr J Nutriti. 2014 Julayi 14; 112: 30-40. Buka okungaqondakali.
  58. IHojsak I, iTokic Pivac V, iMocic Pavic A, iPasini AM, iKolacek S. Bifidobacterium animalis subsp. I-lactis yehluleka ukuvimbela izifo ezivamile ezinganeni ezibhedlela: isifundo esilawulwa ngokungahleliwe, esingaboni kahle, esilawulwa yi-placebo. Ngingu-J J Nutriti Womtholampilo. 2015 Mar; 101: 680-4. Buka okungaqondakali.
  59. U-Eskesen D, uJespersen L, uMichelsen B, uWorwell PJ, uMüller-Lissner S, uMorberg CM. Umphumela wobunzima be-probiotic Bifidobacterium animalis subsp. i-lactis, i-BB-12®, kumvamisa wokuzikhulula ezifundweni ezinempilo ezinemvamisa ephansi yokuzikhandla nokungakhululeki esiswini: ukulawulwa okungahleliwe, okuyimpumputhe, okulawulwa nge-placebo, kweqembu elifanayo. UBr J Nutriti. 2015 uNov 28; 114: 1638-46. Buka okungaqondakali.
  60. UCosteloe K, uHardy P, uJuszczak E, uWilks M, uMillar MR; Ama-Probiotic eqenjini le-Preterm Infants Study. IBifidobacterium breve BBG-001 ezinganeni ezisandulela ukuzalwa: isilingo sesigaba 3 esilawulwa ngokungahleliwe. I-Lancet. 2016 Feb 13; 387: 649-60. Buka okungaqondakali.
  61. Allen SJ, Wareham K, Wang D, Bradley C, Hutchings H, Harris W, Dhar A, Brown H, Foden A, Gravenor MB, Mack D. Lactobacilli kanye ne-bifidobacteria ekuvikeleni isifo sohudo esihambisana namagciwane kanye nohudo lweClostridium difficile kubantu abadala iziguli ezingalaliswayo (i-PLACIDE): isilingo esingahleliwe, esingaboni kabili, esilawulwa nge-placebo, esenzelwe izinto eziningi. I-Lancet. 2013 Okthoba 12; 382: 1249-57. Buka okungaqondakali.
  62. I-Roberfroid MB. Ama-prebiotic nama-probiotic: ingabe kungukudla okusebenzayo? Ngingu-J J Nutriti Womtholampilo. 2000; 71 (6 Suppl): 1682S-7S; ingxoxo 1688S-90S. Buka okungaqondakali.
  63. U-Wang YH, u-Huang Y. Umphumela we-Lactobacillus acidophilus kanye ne-Bifidobacterium bifidum yokwengeza ekwelashweni okujwayelekile okuphindwe kathathu ku-Helicobacter pylori ukuqedwa kanye nezinguquko ezinamandla ezimbali zamathumbu. Umhlaba J Microbiol Biotechnol. 2014; 30: 847-53. Buka okungaqondakali.
  64. U-Wang ZH, uGao QY, uFang JY. Ukuhlaziywa kwemeta kokusebenza nokuphepha kwe-Lactobacillus equkethe ne-Bifidobacterium equkethe ama-probiotic compound ukulungiselela e-Helicobacter pylori therapy yokuqeda. UJ Clin Gastroenterol. 2013; 47: 25-32. Buka okungaqondakali.
  65. IVidelock EJ, iCremonini F. Meta-analysis: ama-probiotic kuhudo oluhambisana nemithi elwa namagciwane. I-Aliment Pharmacol Ther. 2012; 35: 1355-69. Buka okungaqondakali.
  66. UTomasz B, Zoran S, Jaroslaw W, Ryszard M, Marcin G, Robert B, Piotr K, Lukasz K, Jacek P, Piotr G, Przemyslaw P, Michal D. Ukusetshenziswa kwesikhathi eside kwama-probiotic Lactobacillus neBifidobacterium kunomthelela we-prophylactic ku ukwenzeka nobukhali be-pouchitis: isifundo esingahleliwe esingahle senzeke. I-Biomed Res Int. 2014; 2014: 208064. Buka okungaqondakali.
  67. UShavakhi A, Tabesh E, Yaghoutkar A, Hashemi H, Tabesh F, Khodadoostan M, Minakari M, Shavakhi S, Gholamrezaei A. Imiphumela yenhlanganisela yama-multistrain probiotic ekwelashweni okuqukethe i-bismuth ene-quadruple yokwelapha ukutheleleka kwe-Helicobacter pylori: -ukufunda okuyimpumputhe. I-Helicobacter. 2013; 18: 280-4. Buka okungaqondakali.
  68. URerksuppaphol S, uRerksuppaphol L. Isivivinyo esilawulwa ngokungahleliwe sama-probiotic ukunciphisa ukubanda okuvamile ezinganeni zesikole. I-Pediatr Int. 2012; 54: 682-7. Buka okungaqondakali.
  69. URautava S, Kainonen E, Salminen S, Isolauri E. Maternal probiotic supplementation ngesikhathi sokukhulelwa nokuncelisa kunciphisa ubungozi be-eczema enganeni. J Ukungezwani komzimba ne-Immunol. 2012; 130: 1355-60. Buka okungaqondakali.
  70. ULangkamp-Henken B, Rowe CC, Ford AL, Christman MC, Nieves C Jr, Khouri L, Specht GJ, Girard SA, Spaiser SJ, Dahl WJ. I-Bifidobacterium bifidum R0071 iholela engxenyeni enkulu yezinsuku ezinempilo nephesenti eliphansi labafundi abacindezelwe ezifundweni ababika usuku lomkhuhlane / umkhuhlane: isifundo esilawulwa ngokungahleliwe, esingaboni kahle, esilawulwa yi-placebo. UBr J Nutriti. 2015 14; 113: 426-34. Buka okungaqondakali.
  71. UGore C, uCustovic A, uTannock GW, uMunro K, uKerry G, uJohnson K, uPeterson C, uMorris J, uChaloner C, uMurray CS, uWoodcock A. Ukwelashwa kanye nemiphumela yesibili yokuvikela i-probiotic Lactobacillus paracasei noma iBifidobacterium lactis ku-eczema yezinsana Isivivinyo esilawulwa ngokungahleliwe ngokulandela kuze kube yiminyaka engu-3. Ukungezwani komzimba ne-Clin Exp 2012; 42: 112-22. Buka okungaqondakali.
  72. I-Fernández-Carrocera LA, Solis-Herrera A, Cabanillas-Ayón M, Gallardo-Sarmiento RB, García-Pérez CS, Montaño-Rodríguez R, Echániz-Aviles MO. Isilingo somtholampilo esingaboni kabili, esingahleliwe sokuhlola ukusebenza kwama-probiotic ezinganeni ezisanda kuzalwa ezinesisindo esingaphansi kuka-1500 g ekuvikeleni i-necrotising enterocolitis. I-Arch Dis Child Fetal Neonatal Ed 2013; 98: F5-9. Buka okungaqondakali.
  73. Begtrup LM, de Muckadell OB, Kjeldsen J, Christensen RD, Jarbøl DE. Ukwelashwa kwesikhathi eside ngama-probiotic ezigulini zokunakekelwa okuyisisekelo ezine-irritable bowel syndrome - isilingo esilawulwa ngokungahleliwe, esiyimpumputhe, se-placebo. IScand J Gastroenterol 2013; 48: 1127-35. Buka okungaqondakali.
  74. U-Allen SJ, Jordan S, Storey M, Thornton CA, Gravenor MB, Garaiova I, Plummer SF, Wang D, Morgan G. Probiotic ekuvimbeleni i-eczema: isilingo esilawulwa ngokungahleliwe. I-Arch Dis Child 2014; 99: 1014-9. Buka okungaqondakali.
  75. I-Das RR.Singh M, Shafiq N. Probiotic ekwelapheni i-Allergic Rhinitis. I-World Allergy Organisation Journal 2010; 3: 239-244.
  76. USeki M, Igarashi T Fukuda Y Simamura S Kaswashima T Ogasa K. Umphumela weBifidobacterium ubisi olukhulisiwe "njalo" phakathi kweqembu elidala. Ukudla okunomsoco 1978; 31: 379-387.
  77. I-Kageyama T, Nakano Y Tomoda T. Ucwaningo Lokuqhathanisa Lokulawulwa Komlomo Kwamanye Amalungiselelo eBifidobacterium. Imithi neBiology (Japan) 1987; 115: 65-68.
  78. I-Kageyama T, Tomoda T Nakano Y. Umphumela Wokuphathwa KweBifidobacterium Ezigulini Ezineleukemia. IBifidobacteria Microflora. 1984; 3: 29-33.
  79. I-Ballongue J, i-Grill J Baratte-Euloge P. Isenzo sur la flore intestinale de laits fermentés au Bifidobacterium. Lait 1993; 73: 249-256.
  80. Ogata T, Kingaku M Yaeshima T Teraguchi S Fukuwatari Y Ishibashi N Hayasawa H Fujisawa T Lino H. Umphumela wokuphathwa kwe-yogurt ye-Bifidobacterium longum BB536 kumvelo yamathumbu yabantu abadala abaphilile. IMicrob Ecol Health Dis 1999; 11: 41-46.
  81. I-Tomoda T, i-Nakano Y Kageyama T. Ukuhlukahluka kwamaQembu Amancane we-Constant Intestinal Flora ngesikhathi sokuphathwa kwe-Anticancer noma i-Immunosuppressive Drugs. Imithi neBiology (Japan) 1981; 103: 45-49.
  82. UTomoda T, Nakano Y Kageyama T. Ukwanda kwamathumbu weCandida kanye nokutheleleka kweCandida ezigulini ezine-Leukemia: Umphumela weBifidobacterium Administration. IBifidobacteria Microflora 1988; 7: 71-74.
  83. Araya-Kojima Tomoko, Yaeshima Tomoko Ishibashi Norio Shimamura Seiichi Hayasawa Hirotoshi. Imiphumela Engavinjelwe ye-Bifidobacterium longum BB536 ku-Bacteria Yangaphakathi Yengozi. IBifidobacteria Microflora 1995; 14: 59-66.
  84. UNamba K, Yaeshima T Ishibashi N Hayasawa H no Yamazaki Shoji. Imiphumela Engavinjelwe ye-Bifidobacterium longum ku-Enterohemorrhagic Escherichia coli O157: H7. I-Bioscience Microflora 2003; 22: 85-91.
  85. Igarashi M, Iiyama Y Kato R Tomita M Asami N Ezawa I. Umphumela weBifidobacterium longum ne-lactulose emandleni amathambo kumazinga wemodeli ye-osteoporosis ye-ovariectomized. IBifidus 1994; 7: 139-147.
  86. I-Yaeshima T, Takahashi S Ota S Nakagawa K Ishibashi N Hiramatsu A Ohashi T Hayasawa H Iino H. Umphumela weyogathi elimnandi oqukethe iBifidobacterium longum BB536 kumvuthwandaba wokuzikhulula kanye nezici zezindle zabantu abadala abaphilile: Ukuqhathaniswa ne-yogurt ejwayelekile emnandi. UKenko Eiyo Shokuhin Kenkyu 1998; 1 (3/4): 29-34.
  87. I-Yaeshima T, Takahashi S Matsumoto N Ishibashi N Hayasawa H Lino H. Umphumela weyogathi oqukethe iBifidobacterium longum BB536 kumvelo wamathumbu, izici ze-fecal kanye nobuningi bokuzikhipha: Ukuqhathaniswa ne-yogurt ejwayelekile. I-Biosci Microflora 1997; 16: 73-77.
  88. UXiao J, Kondol S Odamaki T Miyaji K Yaeshima T Iwatsuki K Togashi H Benno Y. Umphumela weyogathi oqukethe iBifidobacterium longum BB 536 kumvamisa wokuzikhulula kanye nezici zendle zabantu abadala abaphilile: Ukuwela kabili okuyimpumputhe ngokufunda. Ijenali yaseJapan yeLactic Acid Bacteria 2007; 18: 31-36.
  89. Yaeshima T, Takahashi S Ogura A Konno T Iwatsuki K Ishibashi N Hayasawa H. Umphumela Wobisi Olungavutshiwe Oluqukethe I-Bifidobacterium longum BB536 ku-Defecation Frequency and Fecal Characteristics in Healthy Adult. Ijenali Yokudla Okunomsoco 2001; 4: 1-6.
  90. Ogata T, Nakamura T Anjitsu K Yaeshima T Takahashi S Fukuwatari Y Ishibashi N Hayasawa H Fujisawa T Iino H. Umphumela we-Bifidobacterium longum BB536 yokuphathwa kwemvelo yamathumbu, imvamisa yokukhulula kanye nezimpawu zezinhlayiya zabantu abazinikele. I-Biosci Microflora 1997; 16: 53-58.
  91. Iwabuchi N, Hiruta N Kanetada S Yaeshima T Iwatsuki K Yasui H. Imiphumela ye-Intranasal Administration yeBifidobacterium longum BB536 ku-Mucosal Immune System ku-Respiratory Tract and Influenza Virus Infection kumagundane. Isayensi Yezobisi 2009; 38: 129-133.
  92. Sekine I, Yoshiwara S Homma N Takanori H Tonosuka S. Imiphumela yobisi oluqukethe iBifidobacterium ekuphenduleni kwe-chemiluminescence kwama-peripheral leukocyte futhi kusho umthamo wamangqamuzana abomvu egazi - okungahle kube nendima yeBifidobacterium ekusebenzeni kwama-macrophages. Imithi yokwelashwa (Japan) 1985; 14: 691-695.
  93. USingh, J., Rivenson, A., Tomita, M., Shimamura, S., Ishibashi, N., noReddy, BS Bifidobacterium longum, igciwane lesisu elenza i-lactic livimbela umdlavuza wamakholoni futhi lihlenga ama-biomarker aphakathi kwe-colon carcinogenesis . ICarcinogenesis 1997; 18: 833-841. Buka okungaqondakali.
  94. UReddy, B. S. noRivenson, A. Umphumela wokuvimbela we-Bifidobacterium longum ku-colon, mammary, kanye nesibindi se-carcinogenesis eyenziwe yi-2-amino-3-methylimidazo [4,5-f] quinoline, i-mutagen yokudla. Umdlavuza Res. 9-1-1993; 53: 3914-3918. Buka okungaqondakali.
  95. U-Yamazaki, S., Machii, K., Tsuyuki, S., Momose, H., Kawashima, T., no-Ueda, K. Izimpendulo zomzimba ku-monoassociated Bifidobacterium longum kanye nobudlelwano babo nokuvimbela ukuhlasela kwamagciwane. Ukuzivikela komzimba 1985; 56: 43-50. Buka okungaqondakali.
  96. UKondo, J., Xiao, J. Z., Shirahata, A., Baba, M., Abe, A., Ogawa, K., noShimoda, T. Imiphumela yokuguqula yeBifidobacterium longum BB536 ekuzithumeleni kweziguli esezikhulile zithola ukudla kwangaphakathi. Umhlaba J Gastroenterol 4-14-2013; 19: 2162-2170. Buka okungaqondakali.
  97. U-Akatsu, H., Iwabuchi, N., Xiao, JZ, Matsuyama, Z., Kurihara, R., Okuda, K., Yamamoto, T., noMaruyama, M. Imiphumela Yomtholampilo ye-Probiotic Bifidobacterium longum BB536 ku-Immune Function kanye I-Intrinalinal Microbiota ezigulini esezikhulile ezithola ukondliwa kwe-Tube yangaphakathi. I-JPEN J Umzali Okungenayo Komsoco 11-27-2012; Buka okungaqondakali.
  98. Odamaki, T., Sugahara, H., Yonezawa, S., Yaeshima, T., Iwatsuki, K., Tanabe, S., Tominaga, T., Togashi, H., Benno, Y., noXiao, JZ Effect kokudla ngomlomo kweyogathi okuqukethe iBifidobacterium longum BB536 ezinombolweni zamaseli we-enterotoxigenic Bacteroides fragilis ku-microbiota. I-Anaerobe. 2012; 18: 14-18. Buka okungaqondakali.
  99. Iwabuchi, N., Xiao, J. Z., Yaeshima, T., no-Iwatsuki, K. Ukuphathwa ngomlomo kweBifidobacterium longum kuvuselela ukutheleleka kwegciwane lomkhuhlane kumagundane. Biol.Pharm.Inkunzi. 2011; 34: 1352-1355. Buka okungaqondakali.
  100. USimakachorn, N., Bibiloni, R., Yimyaem, P., Tongpenyai, Y., Varavithaya, W., Grathwohl, D., Reuteler, G., Maire, JC, Blum, S., Steenhout, P., Benyacoub , J., noSchiffrin, i-EJ Ukubekezelelana, ukuphepha, kanye nomphumela kwi-faecal microbiota yefomula yokungenela engezwe ngama-pre-and probiotic ezinganeni ezigula kakhulu. J Pediatr. Gastroenterol. Umsoco. 2011; 53: 174-181. Buka okungaqondakali.
  101. Hascoet, J. M., Hubert, C., Rochat, F., Legagneur, H., Gaga, S., Emady-Azar, S., noSteenhout, P. G. Umphumela wokwakheka kwefomula ekwakhiweni kwe-gut gut microbiota. J Pediatr. Gastroenterol. Umsoco. 2011; 52: 756-762. Buka okungaqondakali.
  102. UFirmansyah, A., Dwipoerwantoro, P. G., Kadim, M., Alatas, S., Conus, N., Lestarina, L., Bouisset, F., noSteenhout, P. Ukukhula okuthuthukisiwe kwezinsana kwasuthisa ubisi oluqukethe ama-synbiotic. I-Asia Pac. J Umtholampilo. 2011; 20: 69-76. Buka okungaqondakali.
  103. UTang, M. L., Lahtinen, S. J., noBoyle, R. J. Ama-Probiotic kanye nama-prebiotic: imiphumela yomtholampilo ezifweni zomzimba. I-Curr.Opin.Izingane. 2010; 22: 626-634. Buka okungaqondakali.
  104. UNamba, K., Hatano, M., Yaeshima, T., Takase, M., noSuzuki, K. Imiphumela ye-Bifidobacterium longum BB536 yokuphathwa kokutheleleka komkhuhlane, umuthi wokugomela umuthi wokugomela umkhuhlane, kanye nokuvikela amasosha omzimba kubantu asebekhulile. I-Biosci.I-Biotechnol.Ibhayoloji. 2010; 74: 939-945. Buka okungaqondakali.
  105. UGianotti, L., Morelli, L., Galbiati, F., Rocchetti, S., Coppola, S., Beneduce, A., Gilardini, C., Zonenschain, D., Nespoli, A., noBraga, M. Isivivinyo esingahleliwe esingahleliwe ekuphathweni kwe-perioperative kwama-probiotic ezigulini zomdlavuza ezi-colorectal. Umhlaba J Gastroenterol. 1-14-2010; 16: 167-175. Buka okungaqondakali.
  106. I-Andrade, S. ne-Borges, N. Umphumela wobisi oluvutshiwe oqukethe iLactobacillus acidophilus neBifidobacterium longum kuma-lipids e-plasma wabesifazane abane-cholesterol ejwayelekile noma ephakeme. I-J.Dairy Res. U-2009; 76: 469-474. Buka okungaqondakali.
  107. URouge, C., Piloquet, H., Butel, MJ, Berger, B., Rochat, F., Ferraris, L., Des, Robert C., Legrand, A., de la Cochetiere, MF, N'Guyen, I-JM, i-Vodovar, i-M, i-Voyer, i-M, i-Darmaun, i-D, ne-Roze, i-JC yokwengezelelwa ngomlomo ngama-probiotic ezinganeni ezisencane kakhulu zokuzalwa ezisisindo sokuzalwa: isilingo esilawulwa ngokungahleliwe, esiyimpumputhe, esilawulwa yi-placebo. NginguJ. J Clin. Nutr. U-2009; 89: 1828-1835. Buka okungaqondakali.
  108. Iwabuchi, N., Takahashi, N., Xiao, JZ, Yonezawa, S., Yaeshima, T., Iwatsuki, K., noHachimura, S. Imiphumela ecindezelayo yeBifidobacterium longum ekukhiqizeni ama-chemokines aheha i-Th2 abangelwa yi-T ukusebenzisana kwamaseli okwethula amaseli. I-FEMS Immunol.Med.Microbiol. U-2009; 55: 324-334. Buka okungaqondakali.
  109. UTakeda, Y., Nakase, H., Namba, K., Inoue, S., Ueno, S., Uza, N., noChiba, T.Ukulawulwa kwe-T-bet kanye nama-molecule okuhlangana okuqinile yiBifidobactrium longum kuthuthukisa ukuvuvukala kwamakholoni. ye-ulcerative colitis. Ukuvuvukala. 2009; 15: 1617-1618. Buka okungaqondakali.
  110. Soh, SE, Aw, M., Gerez, I., Chong, YS, Rauff, M., Ng, YP, Wong, HB, Pai, N., Lee, BW, noShek, LP Probiotic supplementation ku-6 yokuqala izinyanga zokuphila ezisengozini yezinsana zase-Asia - imiphumela ku-eczema nasekuzweleni kwe-atopic eneminyaka engu-1. Ukungezwani komzimba ne-Clin.Exp 2009; 39: 571-578. Buka okungaqondakali.
  111. Odamaki, T., Xiao, JZ, Sakamoto, M., Kondo, S., Yaeshima, T., Iwatsuki, K., Togashi, H., Enomoto, T., noBenno, Y. Ukusatshalaliswa kwezinhlobo ezahlukene ze AmaBacteroides fragilis group kubantu abaneJapan cedar pollinosis. I-Appl.Environ.Microbiol. 2008; 74: 6814-6817. Buka okungaqondakali.
  112. del Giudice, M. M. and Brunese, F. P. Probiotics, prebiotics, kanye nokwaliwa komzimba ezinganeni: yini okusha ngonyaka odlule? J Umtholampilo. Gastroenterol. 2008; 42 Suppl 3 Pt 2: S205-S208. Buka okungaqondakali.
  113. Chouraqui, JP, Grathwohl, D., Labaune, JM, Hascoet, JM, de, Montgolfier, I, Leclaire, M., Giarre, M., noSteenhout, P. Ukuhlolwa kokuphepha, ukubekezelelana, kanye nomphumela wokuvikela ekubanjweni yisisu amafomula ezingane aqukethe imixube yama-probiotic noma ama-probiotic nama-prebiotic esivivinyweni esilawulwa ngokungahleliwe. NginguJ. J Clin. Nutr. 2008; 87: 1365-1373. Buka okungaqondakali.
  114. UMatsumoto, T., Ishikawa, H., Tateda, K., Yaeshima, T., Ishibashi, N., no-Yamaguchi, K. Ukuphathwa ngomlomo kweBifidobacterium longum kuvimbela uPseudomonas aeruginosa sepsis owenziwe ngamathumbu kumagundane. J Appl, iMicrobiol. 2008; 104: 672-680. Buka okungaqondakali.
  115. Odamaki, T., Xiao, JZ, Iwabuchi, N., Sakamoto, M., Takahashi, N., Kondo, S., Miyaji, K., Iwatsuki, K., Togashi, H., Enomoto, T., no I-Benno, Y. Ithonya le-Bifidobacterium longum BB536 elithatha i-faecal microbiota kubantu abane-Japanese cedar pollinosis ngesikhathi se-pollen. UJ Med. IMicrobiol. 2007; 56 (Pt 10): 1301-1308. Buka okungaqondakali.
  116. Iwabuchi, N., Takahashi, N., Xiao, J. Z., Miyaji, K., no-Iwatsuki, K. In vitro Th1 imiphumela ezimele ye-cytokine ezimele ye-Th2 ye-bifidobacteria. I-Microbiol.Immunol. 2007; 51: 649-660. Buka okungaqondakali.
  117. I-Xiao, JZ, Kondo, S., Takahashi, N., Odamaki, T., Iwabuchi, N., Miyaji, K., Iwatsuki, K., ne-Enomoto, T. Izinguquko kumazinga e-plasma TARC ngenkathi yaseJapan yempova yemisedari kanye ubudlelwane nokuthuthukiswa kwezimpawu. Int.Arch.Imishanguzo Yesifo somzimba 2007; 144: 123-127. Buka okungaqondakali.
  118. Odamaki, T., Xiao, JZ, Iwabuchi, N., Sakamoto, M., Takahashi, N., Kondo, S., Iwatsuki, K., Kokubo, S., Togashi, H., Enomoto, T., no Ukushintshashintsha kwe-fecal microbiota kubantu abane-Japanese cedar pollinosis ngenkathi yempova kanye nomthelela wokudla kwama-probiotic. J Ukuphenya. Allergol.Clin.Immunol. 2007; 17: 92-100. Buka okungaqondakali.
  119. I-Xiao, JZ, Kondo, S., Yanagisawa, N., Miyaji, K., Enomoto, K., Sakoda, T., Iwatsuki, K., ne-Enomoto, T. Ukusebenza komtholampilo kwe-probiotic Bifidobacterium longum ekwelapheni izimpawu yokungezwani komzimba nemvukuzane yaseJapan ezifundweni ezihlolwe kuyunithi yokuchayeka kwezemvelo. I-Allergol.Int. 2007; 56: 67-75. Buka okungaqondakali.
  120. UPuccio, G., Cajozzo, C., Meli, F., Rochat, F., Grathwohl, D., noSteenhout, P. Ukuhlolwa komtholampilo kwefomula entsha yokuqala yezinsana eziqukethe iBifidobacterium longum BL999 nama-prebiotics aphilayo. Ukudla okunomsoco 2007; 23: 1-8. Buka okungaqondakali.
  121. Xiao, JZ, Kondo, S., Yanagisawa, N., Takahashi, N., Odamaki, T., Iwabuchi, N., Miyaji, K., Iwatsuki, K., Togashi, H., Enomoto, K., no I-Enomoto, T. Ama-Probiotic ekwelapheni i-cedar pollinosis yaseJapan: isilingo esilawulwa nge-placebo esingaboni kahle. Ukungezwani komzimba ne-Clin.Exp 2006; 36: 1425-1435. Buka okungaqondakali.
  122. Xiao, JZ, Kondo, S., Yanagisawa, N., Takahashi, N., Odamaki, T., Iwabuchi, N., Iwatsuki, K., Kokubo, S., Togashi, H., Enomoto, K., no I-Enomoto, T. Umphumela we-probiotic Bifidobacterium longum BB536 [ilungisiwe] ekwehliseni izimpawu zomtholampilo nasekulinganiseni amazinga e-plasma cytokine e-cedar pollinosis yaseJapane phakathi nenkathi yempova. Isilingo esilawulwa ngokungahleliwe esilawulwa nge-placebo. J Ukuphenya. Allergol.Clin.Immunol. 2006; 16: 86-93. Buka okungaqondakali.
  123. UBennet, R., Nord, C. E., noZetterstrom, R. Ukudluliswa kwamakoloni kwesikhashana kwezinsana ezisanda kuzalwa nge-bifidobacteria ne-lactobacilli elawulwa ngomlomo. I-Acta Paediatr. 1992; 81: 784-787. Buka okungaqondakali.
  124. UZsivkovits, M., Fekadu, K., Sontag, G., Nabinger, U., Huber, WW, Kundi, M., Chakraborty, A., Foissy, H., noKnasmuller, S. Ukuvimbela ukwenziwa kwe-heterocyclic amine Ukulimala kwe-DNA kukholoni nesibindi samagundane ngezinhlobo ezahlukahlukene ze-lactobacillus. ICarcinogenesis 2003; 24: 1913-1918. Buka okungaqondakali.
  125. I-Orrhage, K., Sjostedt, S., neNord, C. E. Umphumela wezithasiselo ezinamagciwane e-lactic acid kanye ne-oligofructose kumathumbu emathumbu ngesikhathi sokuphathwa kwe-cefpodoxime proxetil. J Imithi elwa namagciwane. 2000; 46: 603-612. Buka okungaqondakali.
  126. UXiao JZ, Takahashi S, Odamaki T, et al. Ukutholakala kwama-antibiotic kwamagciwane e-bifidobacterial asatshalaliswa emakethe yaseJapan.I-Biosci Biotechnol Biochem. 2010; 74: 336-42. Buka okungaqondakali.
  127. I-AlFaleh K, Anabrees J, Bassler D, Al-Kharfi T. Ama-Probiotic wokuvimbela i-necrotizing enterocolitis ezinganeni ezizalwe ngaphambi kwesikhathi. Database leCochrane lokubuyekezwa okuhlelekile 2011, Issue 3. Art. Cha: CD005496. INGXENYE: 10.1002 / 14651858.CD005496.pub3. Buka okungaqondakali.
  128. Ama-Tabbers MM, uMilliano I, uRoseboom MG, uBenninga MA. Ingabe iBifidobacterium breve iyasebenza ekwelapheni ukuqunjelwa kwengane? Imiphumela evela ocwaningweni lokushayela indiza. Umsoco J 2011; 10: 19. Buka okungaqondakali.
  129. ULeyer GJ, uLi S, uMubasher ME, et al. Imiphumela ye-Probiotic kwizigameko ezibandayo neze-influenza izehlakalo nobude besikhathi ezinganeni. Izifo zezingane 2009; 124: e172-e179. Buka okungaqondakali.
  130. UMiele E, uPascarella F, uGiannetti E. et al. Umphumela wokulungiselela ama-probiotic (VSL # 3) ekwenziweni nasekugcinweni kokuxolelwa ezinganeni ezine-ulcerative colitis. NginguJ J Gastroenterol 2009; 104: 437-43. Buka okungaqondakali.
  131. UKuhbacher T, Ott SJ, uHelwig U, et al. I-bacterial and fungal microbiota maqondana ne-probiotic therapy (VSL # 3) ku-pouchitis. Amathambo 2006; 55: 833-41. Buka okungaqondakali.
  132. IBibiloni R, uFedorak RN, uTannock GW, et al. Ingxubevange ye-VSL # 3 inciphisa ukuthethelelwa kweziguli ezine-ulcerative colitis. NginguJ J Gastroenterol 2005; 100: 1539-46. Buka okungaqondakali.
  133. UTursi A, uBrandimarte G, uGiorgetti GM, et al. I-balsalazide enomthamo ophansi kanye nokulungiswa kwama-probiotic aphezulu kusebenza kakhulu kune-balsalazide yodwa noma i-mesalazine ekwelapheni i-ulcerative colitis ebukhali kakhulu. IMed Sci Monit 2004; 10: PI126-31. Buka okungaqondakali.
  134. UKato K, Mizuno S, Umesaki Y, et al. Isivivinyo esilawulwa ngokungahleliwe esihlola umthelela wobisi lwe-bifidobacteria-fermented ku-ulcerative colitis esebenzayo. I-Aliment Pharmacol Ther 2004; 20: 1133-41. Buka okungaqondakali.
  135. IMcFarland LV. Ukuhlaziywa kwe-meta kwama-probiotic wokuvimbela isifo sohudo esihambisana namagciwane kanye nokwelashwa kwesifo seClostridium difficile. NginguJ J Gastroenterol 2006; 101: 812-22. Buka okungaqondakali.
  136. U-O'Mahony L, uMcCarthy J, uKelly P, et al. I-Lactobacillus ne-bifidobacterium e-irritable bowel syndrome: izimpendulo zezimpawu nobudlelwano kumaphrofayli e-cytokine. I-Gastroenterology 2005; 128: 541-51. Buka okungaqondakali.
  137. Ishikawa H, Akedo I, Umesaki Y, et al. Isivivinyo esilawulwa ngokungahleliwe somphumela wobisi lwe-bifidobacteria-fermented ku-ulcerative colitis. J Am Coll Nutriti 2003; 22: 56-63. Buka okungaqondakali.
  138. URastall RA. Amagciwane esiswini: abangani nezitha nokuthi ungashintsha kanjani ibhalansi. UJ Nutriti 2004; 134: 2022S-2026S. Buka okungaqondakali.
  139. UMimura T, uRizzello F, uHelwig U, et al. Kanye ngemithi yokwelapha ephezulu ye-probiotic (VSL # 3) yokulondolozwa kokuxolelwa ku-pouchitis ephindaphindayo noma ephikisayo. Umkhuhlane 2004; 53: 108-14. Buka okungaqondakali.
  140. ICremonini F, uDi Caro S, uCovino M, et al. Umphumela wamalungiselelo ahlukile wama-probiotic emiphumeleni emibi ehlobene nokwelashwa kwe-anti-helicobacter pylori: iqembu elifanayo, izimpumputhe eziphindwe kathathu, isifundo esilawulwa nge-placebo. NginguJ J Gastroenterol 2002; 97: 2744-9. Buka okungaqondakali.
  141. USullivan A, uBarkholt L, uNord CE. I-Lactobacillus acidophilus, i-Bifidobacterium lactis ne-Lactobacillus F19 zivimbela ukuphazanyiswa kwemvelo okuhlobene nama-antibiotic kweBacteroides fragilis emathunjini. J Ama-Antimicrob Chemother 2003; 52: 308-11. Buka okungaqondakali.
  142. UKim HJ, uCamilleri M, McKinzie S, et al. Isivivinyo esilawulwa ngokungahleliwe se-probiotic, i-VSL # 3, ekuhambeni kwamathumbu nasezimpawu zesifo sohudo-esivelele kakhulu esiswini. I-Aliment Pharmacol Ther 2003; 17: 895-904. . Buka okungaqondakali.
  143. I-Roberfroid MB. Ama-prebiotic nama-probiotic: ingabe kungukudla okusebenzayo? Ngingu-J J Umtholampilo 2000; 71: 1682S-7S. Buka okungaqondakali.
  144. UGionchetti P, uRizzello F, uVenturi A, et al. I-bacteriotherapy yomlomo njengokwelashwa kwesondlo ezigulini ezine-pouchitis engapheli: isilingo esilawulwa kabili, esilawulwa yi-placebo. I-Gastroenterology 2000; 119: 305-9. Buka okungaqondakali.
  145. URautio M, uJousimies-Somer H, uKauma H, et al. Ithumba lesibindi ngenxa yesisindo seLactobacillus rhamnosus esingahlukaniseki nohlobo lwe-L. rhamnosus GG. I-Clin Infect Dis 1999; 28: 1159-60. Buka okungaqondakali.
  146. UGoldin BR. Izinzuzo Zezempilo zama-probiotic. UBr J Nutriti 1998; 80: S203-7. Buka okungaqondakali.
  147. UKalima P, Masterton RG, uRoddie PH, et al. Ukutheleleka kweLactobacillus rhamnosus enganeni kulandela ukufakelwa umnkantsha wethambo. J Ukuthelela 1996; 32: 165-7. Buka okungaqondakali.
  148. USaxelin M, uChuang NH, uChassy B, et al. ILactobacilli ne-bacteremia eningizimu yeFinland 1989-1992. I-Clin Infect Dis 1996; 22: 564-6. Buka okungaqondakali.
  149. U-Lewis SJ, Freedman AR. Buyekeza i-athikili: ukusetshenziswa kwama-biotherapeutic agents ekuvimbeleni nasekwelapheni izifo zamathumbu. I-Aliment Pharmacol Ther 1998; 12: 807-22. Buka okungaqondakali.
  150. Meydani SN, Ha WK. Imiphumela ye-immunologic yeyogathi. Ngingu-J Clin Nutr 2000; 71: 861-72. Buka okungaqondakali.
  151. U-Isolauri E, u-Arvola T, uSutas Y, et al. Ama-Probiotic ekuphathweni kwe-atopic eczema. Ukungezwani komzimba ne-Clin Exp 2000; 30: 1604-10. Buka okungaqondakali.
  152. UKorschunov VM, uSmeyanov VV, u-Efimov BA, et al. Ukusetshenziswa kokwelashwa kokulungiswa kwe-Bifidobacterium emelana namagciwane emadodeni avezwe kumthamo omkhulu we-gamma-irradiation. UJ Med Microbiol 1996; 44: 70-4. Buka okungaqondakali.
  153. UVenturi A, uGionchetti P, uRizzello F, et al. Umthelela ekwakhiweni kwezimbali zezilwane ngokulungiswa okusha kwama-probiotic: idatha yokuqala yokwelashwa kwesondlo kweziguli ezine-ulcerative colitis. I-Aliment Pharmacol Ther 1999; 13: 1103-8. Buka okungaqondakali.
  154. UPhuapradit P, Varavithya W, Vathanophas K, et al. Ukwehliswa kwesifo se-rotavirus ezinganeni ezithola ifomula eyengezwe nge-bifidobacteria. UJ Med Assoc Thai 1999; 82: S43-8. Buka okungaqondakali.
  155. IHoyos AB. Ukuncipha kwesigameko se-necrotizing enterocolitis esihambisana nokuphathwa kwangaphakathi kweLactobacillus acidophilus neBifidobacterium infantis kuma-neonates egumbini labagula kakhulu. I-Int J Infect Dis 1999; 3: 197-202. Buka okungaqondakali.
  156. UPierce A. I-American Pharmaceutical Association Umhlahlandlela Osebenzayo Wemithi Yemvelo. ENew York: I-Stonesong Press, 1999: 19.
  157. UChen RM, uWu JJ, uLee SC, et al. Ukwandiswa kwe-Bifidobacterium yamathumbu nokucindezelwa kwamagciwane e-coliform ngokungenisa i-yogurt yesikhashana. J Dairy Sci 1999: 82: 2308-14. Buka okungaqondakali.
  158. Ha GY, Yang CH, Kim H, Chong Y. Icala le-sepsis elibangelwa yi-Bifidobacterium longum. UJ Clin Microbiol 1999; 37: 1227-8. Buka okungaqondakali.
  159. IColombel JF, Cortot A, Neut C, Romond C. I-yoghurt ene-Bifidobacterium longum inciphisa imiphumela yamathumbu eyenziwe nge-erythromycin. ILancet 1987; 2: 43.
  160. UHirayama K, Rafter J. Indima yama-bacterium ama-probiotic ekuvimbeleni umdlavuza. Ama-Microbes Angenwe 2000; 2: 681-6. Buka okungaqondakali.
  161. IMacfarlane GT, iCummings JH. Ama-Probiotic nama-prebiotic: ingabe ukulawula imisebenzi yamagciwane emathunjini kungayizuzisa impilo? BMJ 1999; 318: 999-1003. Buka okungaqondakali.
  162. UChiang BL, uSheih YH, uWang LH, et al. Ukwenza ngcono ukuzivikela komzimba ngokusetshenziswa kokudla kwegciwane le-probiotic lactic acid (Bifidobacterium lactis HN019): ukwenziwa nencazelo yezimpendulo zamaseli omzimba. I-Eur J Clin Nutriti 2000; 54: 849-55. Buka okungaqondakali.
  163. ULievin V, uPeiffer I, uHudault S, et al. Izingqinamba zeBifidobacterium ezivela kumuntu osesiswini womuntu microflora emathunjini zenza umsebenzi wokulwa namagciwane. Isisu 2000; 47: 646-52. Buka okungaqondakali.
  164. Arunachalam K, Gill HS, Chandra RK. Ukuthuthukiswa kokuzivikela komzimba ngokwemvelo ngokusetshenziswa kokudla kweBifidobacterium lactis (HN019). I-Eur J Clin Nutriti 2000; 54: 263-7. Buka okungaqondakali.
  165. UBouhnik Y, Pochart P, uMarteau P, et al. Ukubuyiswa kwe-fecal kubantu be-bifidobacterium ephilayo efakwe ubisi oluvutshiwe. I-Gastroenterology 1992; 102: 875-8. Buka okungaqondakali.
  166. Saavedra JM, et al. Ukondliwa kwe-bifidobacterium bifidum ne-streptococcus thermophilus ezinganeni ezisesibhedlela ukuvimbela isifo sohudo nokuchitheka kwe-rotavirus. ILancet 1994; 344: 1046-9. Buka okungaqondakali.
  167. I-Scarpignato C, i-Rampal P. Ukuvimbela nokwelashwa kwesifo sohudo somhambi: Indlela yokwelashwa kwemithi. I-Chemotherapy 1995; 41: 48-81. Buka okungaqondakali.
  168. I-Elmer GW, iSurawicz CM, iMcFarland LV. Ama-Biotherapeutic Agents, Isimo esinganakiwe sokwelashwa nokuvinjelwa kwezifo ezikhethiwe zamathumbu nezangasese. I-JAMA 1996; 275: 870-5. Buka okungaqondakali.
Kugcine ukubuyekezwa - 11/25/2020

Imibhalo Ethandekayo

Izindlela zokupheka ezi-5 ezenziwe ekhaya zokuthambisa izinwele zakho
Impilo

Izindlela zokupheka ezi-5 ezenziwe ekhaya zokuthambisa izinwele zakho

Ire iphi enhle kakhulu eyenziwe ya ekhaya yokuthambi a izinwele ezomile be e uyinika ukubukeka okunom oco futhi okucwebezelayo uku ebenzi a ibhal amu noma i hampu enezithako zemvelo ezikuvumela ukuba ...
Yini i-osteoporosis, izimbangela, izimpawu nokwelashwa
Impilo

Yini i-osteoporosis, izimbangela, izimpawu nokwelashwa

I-o teoporo i yi ifo lapho kuncipha khona amathambo, okwenza amathambo abe ntekenteke ngokwengeziwe, okwandi a amathuba okuphuka. Ezimweni eziningi, i-o teoporo i ayiholeli ekubonakaleni kwezimpawu no...